Intel stock spikes after report of possible US government stake
On Wednesday, Piper Sandler adjusted its stance on Akoya Biosciences Inc (NASDAQ: AKYA), downgrading the company’s stock rating from Overweight to Neutral. The firm also revised its price target to $2.40, a decrease from the previous $2.40. According to InvestingPro data, AKYA shares have declined 29.26% year-to-date, with the stock currently trading at $1.62 and showing oversold conditions based on RSI indicators. This change comes in the wake of the pending acquisition of Akoya by Quanterix (NASDAQ:QTRX), which was announced on January 10th.
The new price target set by Piper Sandler reflects the proposed acquisition value, which is based on 0.318 shares of Quanterix (NASDAQ: QTRX) for each share of Akoya. Piper Sandler has marked this to market to arrive at the updated target. The acquisition process is anticipated to be completed in the second quarter of 2025.
Despite Quanterix’s stock not showing a positive reaction to the acquisition news, the merger of the companies’ proteomics platforms is expected to create a comprehensive solution. This solution will encompass both blood and tissue analysis, suggesting a significant step forward in the field.
Piper Sandler’s analyst pointed out that the strategic rationale behind the acquisition, including the synergies it is expected to generate, supports the belief that the deal will successfully close. The anticipated completion of the acquisition in the upcoming months remains a key factor in the revised rating and price target for Akoya Biosciences shares.
In other recent news, Akoya Biosciences has made significant strides toward its merger with Quanterix Corporation, as the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired, marking a key regulatory milestone. The merger, which involves Quanterix acquiring Akoya in an all-stock transaction, is expected to enhance capabilities in disease diagnostics by combining their technological strengths. However, not all stakeholders are in favor; Kent Lake PR LLC, a major shareholder in Quanterix, opposes the merger, citing concerns about the valuation and financial impact on Quanterix shareholders. The firm argues that the deal undervalues Quanterix and could weaken its financial position, urging the board to reconsider the terms.
In financial terms, the merger aims to generate $40 million in annual cost synergies by 2026, with a projected cash position of $175 million at closing. Both companies expect the merger to drive significant growth, especially in high-demand markets like neurology and oncology. Meanwhile, Akoya has updated its indemnification agreements for directors and officers, expanding protections and aligning with corporate governance best practices. These developments reflect ongoing strategic maneuvers by both companies to strengthen their market positions and operational frameworks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.